

FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A

FIG. 4B

FIG. 4C




FIG. 4F




FIG. 4E




FIG. 4D




FIG. 5A





FIG. 5B



IL-2R GAMMA CHAIN

IL-2R GAMMA CHAIN

FIG. 5C

INTERLEUKINE-2 RECEPTOR




FIG. 6A

IL-2 AND IP 130 SEQUENCE (α -HELICES ARE BOXED)




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8A




FIG. 8B




FIG. 8C






FIG. 8D




- IL-4
- IL-4 + IP130

FIG. 9C




- IL-4
- IL-4 + IP130

FIG. 9B



- IL-4
- IL-4 + IP130

FIG. 9A




△ IP130 + mAb A41 (ANTI-IL-2R β)

■ IL-2 + mAb A41

□ IL-9 + mAb A41

FIG. 9D



△ IP130 + mAb A41 (ANTI-IL-2R β)


■ IL-2 + mAb A41

□ IL-9 + mAb A41

FIG. 9E


1	10	20	30		% HELIX (CIRCULAR DICHROISM)	MAIN MOLECULAR SPECIES	ACTIVITY
APTSSSTKKTKQLQEHLLDQLMLNGINN							
1	30				50% (150 @ 30 μ M) 35% (4 μ M)	TETRAMER (4M-8M, K _d =30-100 μ M) /OCTAMER	+++
	10	30			22% (150 @ 30 μ M)	DIMER (1M-2M, K _d =0.2 μ M) /TETRAMER (2M-4M, K _d =100 μ M)	++
1	22				<2%		-
1	10				0%	DIMER (1M-2M, K _d =50 μ M) (2M-4M, K _d =1.4mM)	-
	5	15			0%	DIMER (1M-2M, K _d =113 μ M)	-
	10	20			0%	MONOMER	ND
	20	20			<5%	MONOMER	+

FIG. 10



IP130

FIG. 11A



IL-2R β

IL-2R β

IP130

FIG. 11B




FIG.12A

BLOT ANTI SHC





FIG. 12B

109020-18/9/260

NO STIMULATION
IL - 2
IP 130
IL - 2 + IP 130



ACTIVATED STATs

FIG.13





FIG. 14

NK CELLS (CD56⁺) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION
(SYNERGY WITH IL-2)


TREATMENT		J31	J32	J33
IL-2 50 nM		14	12	14
	IP130 60 μ M	0	17	≤ 5
	IP130 120 μ M	0	14	< 5
IL-2 50 nM + IP130	60 μ M	26	21	7
IL-2 50 nM + IP130	120 μ M	28	28	28

FIG. 15



EFFECTOR/TARGET = 10

FIG. 16B



EFFECTOR/TARGET = 10

FIG. 16A




FIG. 16C




FIG. 16D




FIG. 16F




FIG. 16E




FIGURE 17




FIGURE 18




FIGURE 19